The Buck Institute study, published in Aging Cell, demonstrates that the APOE2 variant actively bolsters DNA repair pathways in human iPSC-derived GABAergic and glutamatergic neurons while suppressing senescence markers such as p16 and preserving nuclear lamina integrity. This preclinical work—relying on engineered isogenic cell lines and humanized APOE knock-in mice rather than randomized controlled trials—reveals transcriptional upregulation of damage-response genes specifically in APOE2 neurons, contrasting sharply with APOE4's pro-Alzheimer's signatures. Observational population data have long linked APOE2 to exceptional longevity and lower dementia incidence, yet prior coverage fixated on cholesterol transport and amyloid clearance, overlooking this direct genomic maintenance role. Synthesizing these findings with a 2023 Nature Aging review on senescence hallmarks and a large-scale centenarian GWAS in PLOS Genetics (n>2,000, no major conflicts disclosed), the protective effect appears transferable via recombinant APOE2 protein, hinting at extracellular signaling that could bypass genetic limitations. This shifts therapeutic focus toward genome-stabilizing interventions, potentially addressing a root aging driver missed in amyloid-centric trials.